Tyrosine News and Research RSS Feed - Tyrosine News and Research

New personalized DNA-based digital assay has potential to dramatically impact CML management

New personalized DNA-based digital assay has potential to dramatically impact CML management

The outcomes of chronic myeloid leukemia (CML) have dramatically improved as the result of tyrosine kinase inhibitor (TKI) treatment. Use of a TKI regimen can lower the blood CML biomarker to levels imperceptible by current detection methods. For patients in "molecular remission," however, uncertainties remain regarding whether they will relapse or if treatment should be discontinued. [More]
AstraZeneca’s TAGRISSO (osimertinib) approved in EU for metastatic EGFR T790M mutation-positive NSCLC

AstraZeneca’s TAGRISSO (osimertinib) approved in EU for metastatic EGFR T790M mutation-positive NSCLC

AstraZeneca today announced that the European Commission (EC) has granted conditional marketing authorisation for TAGRISSO™ (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). [More]
New way to more efficiently deliver CRISPR/Cas9 therapeutic to mice with Tyrosinemia type I

New way to more efficiently deliver CRISPR/Cas9 therapeutic to mice with Tyrosinemia type I

University of Massachusetts Medical School researchers have found a way to more efficiently delivery a CRISPR/Cas9 therapeutic to adult mice with the metabolic disease Tyrosinemia type I that may also prove to be safer for use in humans. [More]
Mutation or amplification of HER2 gene may lead to lung cancer

Mutation or amplification of HER2 gene may lead to lung cancer

A joint study by University of Colorado Cancer Center and Memorial Sloan Kettering Cancer Center published in the Journal of Thoracic Oncology shows two distinct causes of HER2 activation in lung cancer: mutation of the gene and amplification of the gene. [More]
Simple blood test could help predict emergence of pre-eclampsia in pregnant women

Simple blood test could help predict emergence of pre-eclampsia in pregnant women

Pre-eclampsia is a serious illness associated with pregnancy, which develops after twenty weeks and is associated with defective ingrowing of the placenta within the mother. The dangerous illness is both the second most frequent cause of death in pregnant women, and the reason for severe complications for mother and child, especially during premature births. [More]
BCR–ABL transcript type linked to TKI response, outcomes

BCR–ABL transcript type linked to TKI response, outcomes

The type of BCR–ABL transcript could have an impact on tyrosine kinase inhibitor choice in patients with chronic myeloid leukaemia , according to research published in Blood. [More]
Positive bosutinib response for elderly blast phase CML patient

Positive bosutinib response for elderly blast phase CML patient

A case study suggests that the third-generation tyrosine kinase inhibitor bosutinib may be considered as induction therapy for blast phase chronic myeloid leukaemia in older patients. [More]
Cardiovascular considerations crucial for CML TKI patients

Cardiovascular considerations crucial for CML TKI patients

A review of BCR–ABL1 tyrosine kinase inhibitors highlights the need to consider cardiovascular adverse event risk profiles when prescribing for patients with chronic myeloid leukaemia. [More]
Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib offers significantly longer progression-free survival than everolimus for patients with metastatic non-clear cell renal cell carcinoma, phase II trial results indicate, but treatment effect appears to depend upon key patient characteristics. [More]
TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

Oncology & Hematology Review, the peer-reviewed journal, has published a review highlighting recent data around rociletinib, an investigational therapy in patients with previously treated EGFR mutant-positive non-small cell lung cancer. [More]
Study shows more patients with advanced NSCLC may benefit from pembrolizumab

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

More patients with advanced non-small-cell lung cancer (NSCLC) could benefit from pembrolizumab, says Professor Roy Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, presenting promising results from the pivotal phase 2/3 KEYNOTE-010 trial at the first ESMO Asia Congress in Singapore), in conjunction with a publication in The Lancet. [More]
Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Patients with EGFR-activating mutations in advanced lung cancer seem to benefit more from afatinib than gefitinib as first-line treatment, researchers report at the first ESMO Asia 2015 Congress in Singapore. [More]
Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Mirati Therapeutics, Inc. today announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced. The Company also announced that "glesatinib" is the proposed generic name for MGCD265. [More]
Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Data collected in Japanese and Korean patients included in the global PALOMA3 trial provides evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer. [More]
Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract. [More]
Converting white fat cells into beige fat cells could help fight obesity

Converting white fat cells into beige fat cells could help fight obesity

The body's ability to harness heat production by converting white fat cells, which store calories, into beige fat cells, which burn energy, could help fight obesity, according to researchers at Georgia State University. [More]
Ultra-performance chromatography test aids bosutinib plasma quantification

Ultra-performance chromatography test aids bosutinib plasma quantification

Chinese scientists have developed a fast and sensitive method for the quantification of the tyrosine kinase inhibitor bosutinib in rat blood samples. [More]

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

Phase III trial findings suggest that patients with relapsed or refractory mantle cell lymphoma derive significantly greater benefits from ibrutinib than from temsirolimus therapy. [More]
NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today an expansion of its liquid biopsy testing menu to include two new tests, a NeoLAB Solid Tumor Monitor and a NeoLAB BTK Inhibitor Acquired Resistance test. [More]
Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO (blinatumomab) in adults with acute lymphoblastic leukemia (ALL). [More]
Advertisement
Advertisement